Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article

SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site

(2021) Anna Z Mykytyn et al.   eLife

Characteristics of COVID-19 infection in Beijing

(2020) Sijia Tian et al.   JOURNAL OF INFECTION

SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review

(2020) José Adão Carvalho Nascimento Junior et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2

(2020) Cassandra L. Atzrodt et al.   FEBS Journal

Potential of heparin and nafamostat combination therapy for COVID‐19

(2020) Hidesaku Asakura et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

(2020) Muhammad Adnan Shereen et al.   Journal of Advanced Research

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

(2016) Mizuki Yamamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY